Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Cross-reactive human B cell and T cell epitopes between influenza A and B viruses.

Terajima M, Babon JA, Co MD, Ennis FA.

Virol J. 2013 Jul 26;10:244. doi: 10.1186/1743-422X-10-244. Review.

2.

A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus.

Babon JA, Cruz J, Ennis FA, Yin L, Terajima M.

J Virol. 2012 Sep;86(17):9233-43. doi: 10.1128/JVI.06325-11. Epub 2012 Jun 20. Erratum in: J Virol. 2013 Aug;87(16):9396.

3.

Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.

Rosendahl Huber SK, Camps MG, Jacobi RH, Mouthaan J, van Dijken H, van Beek J, Ossendorp F, de Jonge J.

PLoS One. 2015 Jun 5;10(6):e0127969. doi: 10.1371/journal.pone.0127969. eCollection 2015.

4.

Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus.

Brumeanu TD, Casares S, Bot A, Bot S, Bona CA.

J Virol. 1997 Jul;71(7):5473-80.

5.
6.

Human cytotoxic T-lymphocyte repertoire to influenza A viruses.

Jameson J, Cruz J, Ennis FA.

J Virol. 1998 Nov;72(11):8682-9.

7.

MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response.

Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, Philip R.

PLoS One. 2012;7(11):e48484. doi: 10.1371/journal.pone.0048484. Epub 2012 Nov 7.

8.

Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections.

Zhong W, Liu F, Dong L, Lu X, Hancock K, Reinherz EL, Katz JM, Sambhara S.

PLoS One. 2010 May 11;5(5):e10583. doi: 10.1371/journal.pone.0010583.

9.
10.

Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold.

Valkenburg SA, Gras S, Guillonneau C, La Gruta NL, Thomas PG, Purcell AW, Rossjohn J, Doherty PC, Turner SJ, Kedzierska K.

PLoS Pathog. 2010 Aug 12;6(8):e1001039. doi: 10.1371/journal.ppat.1001039.

11.
12.

Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus.

Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW.

J Immunol. 2008 Feb 1;180(3):1758-68.

14.

Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.

Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A.

PLoS Pathog. 2009 Mar;5(3):e1000350. doi: 10.1371/journal.ppat.1000350. Epub 2009 Mar 20.

15.

Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.

Fernández IM, Harmsen M, Benaissa-Trouw BJ, Stuij I, Puyk W, Meloen RH, Snippe H, Kraaijeveld CA.

Vaccine. 1998 Oct;16(16):1531-6.

PMID:
9711800
16.

Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus.

Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2008 Jun;82(11):5161-6. doi: 10.1128/JVI.02694-07. Epub 2008 Mar 19.

18.

Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice.

Wolf AI, Mozdzanowska K, Williams KL, Singer D, Richter M, Hoffmann R, Caton AJ, Otvos L, Erikson J.

PLoS One. 2011;6(12):e28445. doi: 10.1371/journal.pone.0028445. Epub 2011 Dec 13.

19.
20.

Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses.

Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ, Rossjohn J, Kedzierska K.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12599-604. doi: 10.1073/pnas.1007270107. Epub 2010 Jun 28.

Items per page

Supplemental Content

Write to the Help Desk